This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Families with two members identified with CLL by the Utah Population Data Base/Utah Cancer Registry will be asked to join the Utah Familial CLL Registry. Consenting family members provide the following information: medical and family history/exposure information via questionnaire, consent for medical record reveiw and blood/mouth rinse samples. Blood from subjects with CLL will be used to confirm diagnositic and prognostic factors. That from affected family members will be analyzed for clonal lymphocytosis undetermined significance (CLUS), and members will be classified as CLUS+, or CLUS- controls. DNA, RNA and serum from participants will be banked for studies in this proposal as well as for future studies, depending upon participant wishes. Familial CLL will be characterized and compared to sporadic CLL. Clinical, immunophenotypic and molecular prognostic factors will be analyzed. Detailed clinical and molecular characterization of the CLUS+ participants and cells will be performed to ascertain steps in the multi-step pathogenesis of familial CLL. Simulated linkage analysis to determine design parameters for future genetic linkage studies will also be performed using the pedigree data generated by the Utah Familial CLL Registry.
Showing the most recent 10 out of 535 publications
